Merck Cuts Full-Year Profit Forecast as Acquisition Costs Weigh on Bottom Line

Merck slashed its profit outlook for the year due to charges tied to its acquisition of cancer biotech company Terns Pharmaceuticals.

本文内容来自外部来源，点击「继续访问」将跳转到原始发布站点。